Telik cancer drug fails trials; stock plummets 
Telik Inc. said on Tuesday that its experimental cancer drug failed to improve survival in patients with advanced lung cancer or in patients with ovarian cancer, sending its stock plunging more than 70 percent in pre-market trading.

–> Click Here for a FREE Money Management Email Course